Cellectis Sa Stock Current Liabilities
| CMVLF Stock | USD 3.12 0.54 20.93% |
Fundamental analysis of Cellectis allows traders to better anticipate movements in Cellectis' stock price by examining its financial health and performance throughout various phases of its business cycle.
Cellectis |
Cellectis SA Company Current Liabilities Analysis
Cellectis' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Cellectis Current Liabilities | 58 M |
Most of Cellectis' fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cellectis SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, Cellectis SA has a Current Liabilities of 58 M. This is 96.69% lower than that of the Healthcare sector and 89.32% lower than that of the Biotechnology industry. The current liabilities for all United States stocks is 99.27% higher than that of the company.
Cellectis Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cellectis' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Cellectis could also be used in its relative valuation, which is a method of valuing Cellectis by comparing valuation metrics of similar companies.Cellectis is currently under evaluation in current liabilities category among its peers.
Cellectis Fundamentals
| Return On Equity | -0.56 | |||
| Return On Asset | -0.24 | |||
| Operating Margin | (6.01) % | |||
| Current Valuation | 82.79 M | |||
| Shares Outstanding | 55.59 M | |||
| Shares Owned By Institutions | 9.80 % | |||
| Price To Earning | (13.64) X | |||
| Price To Book | 0.79 X | |||
| Price To Sales | 4.79 X | |||
| Revenue | 57.29 M | |||
| Gross Profit | 34.18 M | |||
| EBITDA | (103.2 M) | |||
| Net Income | (114.2 M) | |||
| Cash And Equivalents | 153.13 M | |||
| Cash Per Share | 3.37 X | |||
| Total Debt | 18.77 M | |||
| Debt To Equity | 0.52 % | |||
| Current Ratio | 3.17 X | |||
| Book Value Per Share | 3.00 X | |||
| Cash Flow From Operations | (104.56 M) | |||
| Earnings Per Share | (2.95) X | |||
| Number Of Employees | 294 | |||
| Beta | 2.0 | |||
| Market Capitalization | 131.39 M | |||
| Total Asset | 382.08 M | |||
| Retained Earnings | (206 M) | |||
| Working Capital | 239 M | |||
| Current Asset | 297 M | |||
| Current Liabilities | 58 M | |||
| Z Score | 4.2 | |||
| Net Asset | 382.08 M |
About Cellectis Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cellectis SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cellectis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cellectis SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Additional Information and Resources on Investing in Cellectis Pink Sheet
When determining whether Cellectis SA is a strong investment it is important to analyze Cellectis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cellectis' future performance. For an informed investment choice regarding Cellectis Pink Sheet, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cellectis SA. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.